24 Mar 2016 15:22
PuriCore plc
("PuriCore" or the "Company")
Annual Report and Accounts Available
24 March 2016 - PuriCore plc (AIM: PURI), confirms that, further to the announcement of its Final Results today, an electronic copy of the Annual Report and Accounts for the year ended 31 December 2015 is now available on the Company's website www.puricore.com.
-Ends-
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
| |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | |||
| |||
FTI Consulting | +44 (0) 20 3727 1000 |
| |
Simon Conway / Mo Noonan / Victoria Foster Mitchell |
| ||
| |||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| |
Aubrey Powell / Jen Boorer / Tom Smale |
| ||
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies, based on its proprietary hypochlorous acid platform technology. The Company has initiated a drug development program based upon its proprietary technology and formulations at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including potential rare disease indications. Currently, the Company serves the Supermarket Retail sector and Wound Care market (as a medical device) utilizing different formulations. For more information, visit www.puricore.com.